ELI LILLY AND COMPANY Lessee, Operating Lease, Liability, Undiscounted Excess Amount
ELI LILLY AND COMPANY (LLY) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $300.40 million as of 2024-12-31, per its 10-K filed 2025-02-19.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2025-02-19
- 2024-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $300.40M.
- 2023-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $284.80M.
- 2022-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $95.20M.
- 2021-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $90.10M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2024-12-31 | $300.40M 10-K · filed 2025-02-19 |
| 2023-12-31 | $284.80M 10-K · filed 2024-02-21 |
| 2022-12-31 | $95.20M 10-K · filed 2023-02-22 |
| 2021-12-31 | $90.10M 10-K · filed 2022-02-23 |
| 2020-12-31 | $97.40M 10-K · filed 2021-02-17 |
| 2019-12-31 | $112.00M 10-K · filed 2020-02-19 |
| 2019-09-30 | $107.30M 10-Q · filed 2019-10-25 |
| 2019-06-30 | $108.00M 10-Q · filed 2019-08-02 |
| 2019-03-31 | $109.50M 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |